Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular and Cellular Pediatrics
Published in: Molecular and Cellular Pediatrics 1/2016

Open Access 01-12-2016 | Mini review

Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome

Authors: Bruno P. Chumpitazi, Robert J. Shulman

Published in: Molecular and Cellular Pediatrics | Issue 1/2016

Login to get access

Abstract

Irritable bowel syndrome (IBS) affects a large number of children throughout the world. The symptom expression of IBS is heterogeneous, and several factors which may be interrelated within the IBS biopsychosocial model play a role. These factors include visceral hyperalgesia, intestinal permeability, gut microbiota, psychosocial distress, gut inflammation, bile acids, food intolerance, colonic bacterial fermentation, and genetics. The molecular and cellular mechanisms of these factors are being actively investigated. In this mini-review, we present updates of these mechanisms and, where possible, relate the findings to childhood IBS. Mechanistic elucidation may lead to the identification of biomarkers as well as personalized childhood IBS therapies.
Literature
1.
Saps M, Seshadri R, Sztainberg M, Schaffer G, Marshall BM, Di Lorenzo C (2009) A prospective school-based study of abdominal pain and other common somatic complaints in children. J Pediatr 154(3):322–326CrossRefPubMed
2.
Schwille IJ, Giel KE, Ellert U, Zipfel S, Enck P (2009) A community-based survey of abdominal pain prevalence, characteristics, and health care use among children. Clin Gastroenterol Hepatol 7(10):1062–1068CrossRefPubMed
3.
Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, Walker LS (2006) Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 130(5):1527–1537CrossRefPubMed
4.
Wong G, Chiou EH, Shulman RJ, Chumpitazi BP (2013) Decreased yield of esophagogastroduodenoscopy in children with gastroparesis. J Clin Gastroenterol 48(3):231–235CrossRef
5.
6.
7.
Self MM, Czyzewski DI, Chumpitazi BP, Weidler EM, Shulman RJ (2014) Subtypes of irritable bowel syndrome in children and adolescents. Clin Gastroenterol Hepatol 12(9):1468–1473PubMedCentralCrossRefPubMed
8.
Giannetti E, de’Angelis G, Turco R, Campanozzi A, Pensabene L, Salvatore S, de Seta F, Staiano A (2014) Subtypes of irritable bowel syndrome in children: prevalence at diagnosis and at follow-up. J Pediatr 164(5):1099–1103, e1091CrossRefPubMed
9.
Chumpitazi BP, Hollister EB, Oezguen N, Tsai CM, McMeans AR, Luna RA, Savidge TC, Versalovic J, Shulman RJ (2014) Gut microbiota influences low fermentable substrate diet efficacy in children with irritable bowel syndrome. Gut Microbes 5(2):165–175PubMedCentralCrossRefPubMed
10.
Rodriguez-Fandino O, Hernandez-Ruiz J, Schmulson M (2010) From cytokines to toll-like receptors and beyond—current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil 16(4):363–373PubMedCentralCrossRefPubMed
11.
Moloney RD, O’Mahony SM, Dinan TG, Cryan JF (2015) Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities. Front Psychiatry. doi:10.​3389/​fpsyt.​2015.​00015
12.
Farmer AD, Aziz Q (2014) Mechanisms and management of functional abdominal pain. J R Soc Med 107(9):347–354PubMed
13.
Faure C, Wieckowska A (2007) Somatic referral of visceral sensations and rectal sensory threshold for pain in children with functional gastrointestinal disorders. J Pediatr 150(1):66–71CrossRefPubMed
14.
Iovino P, Tremolaterra F, Boccia G, Miele E, Ruju FM, Staiano A (2009) Irritable bowel syndrome in childhood: visceral hypersensitivity and psychosocial aspects. Neurogastroenterol Motil 21(9):940–e974CrossRefPubMed
15.
Williams AE, Czyzewski DI, Self MM, Shulman RJ (2015) Are child anxiety and somatization associated with pain in pain-related functional gastrointestinal disorders? J Health Psychol 20(4):369–379CrossRefPubMed
16.
Williams AE, Heitkemper M, Self MM, Czyzewski DI, Shulman RJ (2013) Endogenous inhibition of somatic pain is impaired in girls with irritable bowel syndrome compared with healthy girls. J Pain 14(9):921–930PubMedCentralCrossRefPubMed
17.
Sandrini G, Milanov I, Malaguti S, Nigrelli MP, Moglia A, Nappi G (2000) Effects of hypnosis on diffuse noxious inhibitory controls. Physiol Behav 69(3):295–300CrossRefPubMed
18.
Palsson OS, Turner MJ, Johnson DA, Burnett CK, Whitehead WE (2002) Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Dig Dis Sci 47(11):2605–2614CrossRef
19.
Rutten JM, Reitsma JB, Vlieger AM, Benninga MA (2013) Gut-directed hypnotherapy for functional abdominal pain or irritable bowel syndrome in children: a systematic review. Arch Dis Child 98(4):252–257CrossRefPubMed
20.
Corsetti M, Akyuz F, Tack J (2015) Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome. Neurogastroenterol Motil 27(10):1354–1370CrossRefPubMed
21.
Koletzko S, Baltserovich N, Shcherbina A, Galustyan A, Berolotti M, Zinzi D, Poggiali G, Scartoni S (2015) A randomised, double-blind, placebo-controlled phase II study to evaluate the efficacy of 7 days of orally administered nepadutant in infants with colic—the NO-CRY study. Gastroenterology 148:S423CrossRef
22.
Savino F, Castagno E, Bretto R, Brondello C, Palumeri E, Oggero R (2005) A prospective 10-year study on children who had severe infantile colic. Acta Paediatr Suppl 94(449):129–132CrossRefPubMed
23.
Harrington AM, Hughes PA, Martin CM, Yang J, Castro J, Isaacs NJ, Blackshaw LA, Brierley SM (2011) A novel role for TRPM8 in visceral afferent function. Pain 152(7):1459–1468CrossRefPubMed
24.
Khanna R, MacDonald JK, Levesque BG (2014) Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 48(6):505–512PubMed
25.
Kline RM, Kline JJ, Di Palma J, Barbero GJ (2001) Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr 138:125–128CrossRef
26.
Kearns GL, Chumpitazi BP, Abdel-Rahman SM, Garg U, Shulman RJ (2015) Systemic exposure to menthol following administration of peppermint oil to paediatric patients. BMJ Open. doi: 10.​1136/​bmjopen-2015-008375.
27.
Gazouli M, Wouters MM, Kapur-Pojskic L, Bengtson MB, Friedman E, Nikcevic G, Demetriou CA, Mulak A, Santos J, Niesler B (2016) Lessons learned—resolving the enigma of genetic factors in IBS. Nat Rev Gastroenterol Hepatol. doi:10.​1038/​nrgastro.​2015.​206
28.
29.
Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA (2001) Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 121:799–804CrossRefPubMed
30.
Margolis KG, Stevanovic K, Li Z, Yang QM, Oravecz T, Zambrowicz B, Jhaver KG, Diacou A, Gershon MD (2014) Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut 63(6):928–937PubMedCentralCrossRefPubMed
31.
Gershon MD, Tack J (2007) The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132(1):397–414CrossRefPubMed
32.
Kumar S, Ranjan P, Mittal B, Ghoshal UC (2012) Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls. J Gastrointestin Liver Dis 21(1):31–38PubMed
33.
Zhang ZF, Duan ZJ, Wang LX, Yang D, Zhao G, Zhang L (2014) The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: a meta-analysis of 25 studies. BMC Gastroenterol. doi:10.​1186/​1471-230X-14-23
34.
Bertrand J, Ghouzali I, Guerin C, Bole-Feysot C, Gouteux M, Dechelotte P, Ducrotte P, Coeffier M (2015) Glutamine restores tight junction protein Claudin-1 expression in colonic mucosa of patients with diarrhea-predominant irritable bowel syndrome. J Parenter Enteral Nutr doi:10.​1177/​0148607115587330​
35.
Shulman RJ, Eakin MN, Czyzewski DI, Jarrett M, Ou CN (2008) Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome. J Pediatr 153(5):646–650PubMedCentralCrossRefPubMed
36.
37.
Zhou Q, Costinean S, Croce CM, Brasier AR, Merwat S, Larson SA, Basra S, Verne GN (2015) MicroRNA 29 targets nuclear factor-kappaB-repressing factor and Claudin 1 to increase intestinal permeability. Gastroenterology 148(1):158–169, e158PubMedCentralCrossRefPubMed
38.
Francavilla R, Miniello V, Magista AM, De Canio A, Bucci N, Gagliardi F, Lionetti E, Castellaneta S, Polimeno L, Peccarisi L, Indrio F, Cavallo L (2010) A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 126(6):e1445–e1452CrossRefPubMed
39.
Leffler DA, Kelly CP, Green PH, Fedorak RN, DiMarino A, Perrow W, Rasmussen H, Wang C, Bercik P, Bachir NM, Murray JA (2015) Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology 148(7):1311–1319, e1316CrossRef
40.
41.
Wouters MM, Vicario M, Santos J (2016) The role of mast cells in functional GI disorders. Gut 65(1):155–168CrossRefPubMed
42.
Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, Rhee JC (2006) Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 21(1 Pt 1):71–78CrossRefPubMed
43.
Piche T, Saint-Paul MC, Dainese R, Marine-Barjoan E, Iannelli A, Montoya ML, Peyron JF, Czerucka D, Cherikh F, Filippi J, Tran A, Hebuterne X (2008) Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 57(4):468–473CrossRefPubMed
44.
Di Nardo G, Barbara G, Cucchiara S, Cremon C, Shulman RJ, Isoldi S, Zecchi L, Drago L, Oliva S, Saulle R, Barbaro MR, Stronati L (2014) Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with IBS. Neurogastroenterol Motil 26(2):196–204CrossRef
45.
Ebrahimi Daryani N, Hashemian F, Afkham M, Habibollahi P, Keramati MR, Fereshtehnejad SM, Bashashati M (2009) Mast cell stabilizers as a potential treatment for Irritable bowel syndrome: a randomized placebo-controlled clinical trial. DARU J Pharmaceut Sci 17(2):72–78
46.
Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE (2010) The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 59(9):1213–1221CrossRefPubMed
47.
48.
Vicario M, Gonzalez-Castro AM, Martinez C, Lobo B, Pigrau M, Guilarte M, de Torres I, Mosquera JL, Fortea M, Sevillano-Aguilera C, Salvo-Romero E, Alonso C, Rodino-Janeiro BK, Soderholm JD, Azpiroz F, Santos J (2015) Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. Gut 64(9):1379–1388CrossRef
49.
Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I (2002) Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122:1778–1783CrossRefPubMed
50.
Ohman L, Isaksson S, Lindmark AC, Posserud I, Stotzer PO, Strid H, Sjovall H, Simren M (2009) T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 104(5):1205–1212CrossRefPubMed
51.
Dinan TG, Clarke G, Quigley EM, Scott LV, Shanahan F, Cryan J, Cooney J, Keeling PW (2008) Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol 103(10):2570–2576CrossRefPubMed
52.
Zhen Y, Chu C, Zhou S, Qi M, Shu R (2015) Imbalance of tumor necrosis factor-alpha, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea. Mol Med Rep 12(4):5239–5245PubMed
53.
Jarczak J, Kosciuczuk EM, Lisowski P, Strzalkowska N, Jozwik A, Horbanczuk J, Krzyzewski J, Zwierzchowski L, Bagnicka E (2013) Defensins: natural component of human innate immunity. Hum Immunol 74(9):1069–1079CrossRefPubMed
54.
Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, Musial F, Dobos GJ (2009) Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 104(2):404–410CrossRef
55.
El-Salhy M, Gilja OH, Gundersen D, Hatlebakk JG, Hausken T (2014) Interaction between ingested nutrients and gut endocrine cells in patients with irritable bowel syndrome (review). Int J Mol Med 34(2):363–371PubMedCentralPubMed
56.
El-Salhy M, Lillebo E, Reinemo A, Salmelid L (2009) Ghrelin in patients with irritable bowel syndrome. Int J Mol Med 23(6):703–707CrossRefPubMed
57.
Ohman L, Stridsberg M, Isaksson S, Jerlstad P, Simren M (2012) Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol 107(3):440–447CrossRefPubMed
58.
Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG (2014) A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146(1):67–75, e65CrossRefPubMed
59.
Murray K, Wilkinson-Smith V, Hoad C, Costigan C, Cox E, Lam C, Marciani L, Gowland P, Spiller RC (2014) Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol 109(1):110–119PubMedCentralCrossRef
60.
Huertas-Ceballos A, Logan S, Bennett C, Macarthur C (2008) Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev 1:CD003017. doi:10.​1002/​14651858.​CD003017.​pub2 PubMed
61.
Chumpitazi BP, Cope JL, Hollister EB, Tsai CM, McMeans AR, Luna RA, Versalovic J, Shulman RJ (2015) Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther 42(4):418–427CrossRefPubMed
62.
Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG (2015) Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64(1):93–100CrossRefPubMed
63.
Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K (2012) Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 142(8):1510–1518CrossRefPubMed
64.
Kumar S, Ranjan P, Mittal B, Singh R, Ghoshal UC (2012) Lactase persistence/non-persistence genetic variants in irritable bowel syndrome in an endemic area for lactose malabsorption. J Gastroenterol Hepatol 27(12):1825–1830CrossRefPubMed
65.
Yang J, Fox M, Cong Y, Chu H, Zheng X, Long Y, Fried M, Dai N (2014) Lactose intolerance in irritable bowel syndrome patients with diarrhoea: the roles of anxiety, activation of the innate mucosal immune system and visceral sensitivity. Aliment Pharmacol Ther 39(3):302–311CrossRefPubMed
66.
Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW (2011) Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 8:CD003460. doi:10.​1002/​14651858.​CD003460.​pub3 PubMed
67.
Enck P, Junne F, Klosterhalfen S, Zipfel S, Martens U (2010) Therapy options in irritable bowel syndrome. Eur J Gastroenterol Hepatol 22(12):1402–1411PubMed
68.
Chouinard LE (2011) The role of psyllium fibre supplementation in treating irritable bowel syndrome. Can J Diet Pract Res 72(1):e107–e114CrossRefPubMed
69.
Eswaran S, Muir J, Chey WD (2013) Fiber and functional gastrointestinal disorders. Am J Gastroenterol 108(5):718–727CrossRefPubMed
70.
Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P (2008) Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 337:a2313PubMedCentralCrossRefPubMed
71.
Bijkerk CJ, Muris JW, Knottnerus JA, Hoes AW, de Wit NJ (2004) Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 19(3):245–251CrossRefPubMed
72.
Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW (2009) Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ 339:b3154PubMedCentralCrossRef
73.
Shulman RJ, Hollister EB, Cain K, Czyzewski D, Self MM, Weidler EM, Devaraj S, Versalovic J, Heitkemper M (2015) Randomized, double blind trial of psyllium fiber in children with irritable bowel syndrome. Gastroenterol 148(4):S-120 (Abstract)CrossRef
74.
Camilleri M, Gores GJ (2015) Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol 309(4):G209–G215CrossRefPubMed
75.
Appleby RN, Walters JR (2014) The role of bile acids in functional GI disorders. Neurogastroenterol Motil 26(8):1057–1069CrossRefPubMed
76.
Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ, Cook IJ (2002) The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol Gastrointest Liver Physiol 282(3):G443–G449CrossRefPubMed
77.
Keely SJ, Scharl MM, Bertelsen LS, Hagey LR, Barrett KE, Hofmann AF (2007) Bile acid-induced secretion in polarized monolayers of T84 colonic epithelial cells: structure-activity relationships. Am J Physiol Gastrointest Liver Physiol 292(1):G290–G297CrossRefPubMed
78.
Slattery SA, Niaz O, Aziz Q, Ford AC, Farmer AD (2015) Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 42(1):3–11CrossRefPubMed
79.
Shin A, Camilleri M, Vijayvargiya P, Busciglio I, Burton D, Ryks M, Rhoten D, Lueke A, Saenger A, Girtman A, Zinsmeister AR (2013) Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 11(10):1270–1275, e1271PubMedCentralCrossRefPubMed
80.
Hofmann AF, Loening-Baucke V, Lavine JE, Hagey LR, Steinbach JH, Packard CA, Griffin TL, Chatfield DA (2008) Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J Pediatr Gastroenterol Nutr 47(5):598–606CrossRefPubMed
81.
Bajor A, Tornblom H, Rudling M, Ung KA, Simren M (2015) Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 64(1):84–92CrossRefPubMed
82.
Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA (2015) The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 41(1):54–64CrossRefPubMed
83.
Rao AS, Wong BS, Camilleri M, Odunsi-Shiyanbade ST, McKinzie S, Ryks M, Burton D, Carlson P, Lamsam J, Singh R, Zinsmeister AR (2010) Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 139(5):1549–1558, 1558 e1541PubMedCentralCrossRefPubMed
84.
Chey WD, Camilleri M, Chang L, Rikner L, Graffner H (2011) A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 106(10):1803–1812PubMedCentralCrossRefPubMed
85.
Rajilic-Stojanovic M, Jonkers DM, Salonen A, Hanevik K, Raes J, Jalanka J, de Vos WM, Manichanh C, Golic N, Enck P, Philippou E, Iraqi FA, Clarke G, Spiller RC, Penders J (2015) Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol 110(2):278–287PubMedCentralCrossRefPubMed
86.
Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A, Petrosino JF, Highlander S, Gibbs R, Lynch SV, Shulman RJ, Versalovic J (2011) Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141(5):1782–1791PubMedCentralCrossRefPubMed
87.
Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141(5):1792–1801CrossRefPubMed
88.
Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP (2015) Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci. doi:10.​3389/​fncel.​2015.​00392
89.
Horvath A, Dziechciarz P, Szajewska H (2011) Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 33(12):1302–1310CrossRefPubMed
90.
Guandalini S, Magazzu G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S, Sibal A, Romano C, Canani RB, Lionetti P, Setty M (2010) VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 51(1):24–30CrossRefPubMed
Metadata
Title
Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome
Authors
Bruno P. Chumpitazi
Robert J. Shulman
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Molecular and Cellular Pediatrics / Issue 1/2016
Electronic ISSN: 2194-7791
DOI
https://doi.org/10.1186/s40348-016-0036-8

Other articles of this Issue 1/2016

Molecular and Cellular Pediatrics 1/2016 Go to the issue

Review

Neutrophil elastase and matrix metalloproteinase 12 in cystic fibrosis lung disease

Review

Linking bronchopulmonary dysplasia to adult chronic lung diseases: role of WNT signaling

Mini review

Mesenchymal stem/stromal cells—a key mediator for regeneration after perinatal morbidity?

MINI REVIEW

Mesenchymal stromal cells in the development and therapy of bronchopulmonary dysplasia

Mini review

The impact of hypoxia on intestinal epithelial cell functions: consequences for invasion by bacterial pathogens

Mini review

The puzzle of immune phenotypes of childhood asthma